Mar 9, 2011 by Brian Orelli, PhDSlicing and Dicing Your Way through Drug DevelopmentAeterna Zentaris has the right idea.
Mar 9, 2011 by Brian Orelli, PhDThe Case of the Not-So-Mysterious Hep C DataThere's something you should know about the abstract that sent Pharmasset skyward.
Mar 8, 2011 by Brian Orelli, PhDThe Big Winner in Tiny MergersSwallowing a company half its size won't be easy for Accuray.
Mar 7, 2011 by Brian Orelli, PhDKids, Vaccines, and Deaths a Bad CombinationPfizer and Sanofi may not to be to blame.
Mar 7, 2011 by Brian Orelli, PhDWill Benlysta Get Past the FDA?That might not even be the right question.
Mar 4, 2011 by Brian Orelli, PhDPfizer's Biggest Shot at Lipitor 2.0It might need a little help from competitors.
Mar 3, 2011 by Brian Orelli, PhDAmylin Comes Up Snake EyesWhen 0.2 percentage points means so much...
Mar 2, 2011 by Brian Orelli, PhDWhen Will Dendreon Make Money?Not for awhile ... it's a biotech thing.
Mar 1, 2011 by Brian Orelli, PhDUncle Sam Gives Novavax a Big Hand UpCash is everything for a development-stage drugmaker.
Feb 28, 2011 by Brian Orelli, PhDNext-Generation Drug Technologies Battle It OutAlnylam and Sangamo BioSciences have different ways to manipulate proteins to fight disease.
Feb 28, 2011 by Brian Orelli, PhD6 Health-Care IPOs; 3 Worth WatchingLook for the ones fast out of the gate.
Feb 28, 2011 by Brian Orelli, PhDThe New Biotech Binary Event"Refuse to file" letters are on the rise.
Feb 28, 2011 by Brian Orelli, PhDLook Out for Big Growth From This DrugRegeneron's Arcalyst takes a step forward toward a wider audience.
Feb 28, 2011 by Brian Orelli, PhDPharma's Newest Acquisition TargetsShare buybacks in! Licensing deals out?
Feb 28, 2011 by Brian Orelli, PhDJohnson & Johnson Parties Like It's 1982Crisis management; we've been here before.
Feb 25, 2011 by Brian Orelli, PhDMinor Delay, Major Missed OpportunityProtalix and Pfizer's drug gets delayed.
